Brief: Halozyme Therapeutics Q4 Operating Expenses USD 122.507 Million
18/02/2025 21:01
Feb 18 (Reuters) - Halozyme Therapeutics Q4 operating income USD 175.501 million. * Q4 net income USD 137.012 million * Q4 pretax profit USD 178.214 million * outlook FY revenue USD 1,150-1,225 million
Recent news on Halozyme Therapeutics
See all newsUS RESEARCH ROUNDUP-BlackRock, Evercore, Goldman Sachs
Halozyme wins court order to block Merck's injected Keytruda in select European markets (updated)
US STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
Halozyme wins court order to block Merck's injected Keytruda in select European markets